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Recent studies on cation transport in blood cells indicate that alterations in the cation content of erythrocytes serve as genetic markers for hypertensive diathesis and possibly provide insight into the pathogenesis of the disease. Many observations focus on the mechanism by which sodium and potassium metabolism affects blood pressure in humans. Some studies suggest that the Na,K-ATPase (EC 3.6.1.37) is suppressed in the blood vessels of hypertensive individuals; in other models the Na,K pump rate is thought to be increased secondary to increased passive Na permeability of the plasma membrane of vascular smooth muscle. The humoral pressor natriuretic factor in salt-sensitive patients may itself be an inhibitor of Na,K-ATPase (1). that internal sodium is required for the pump uptake of potassium; three sodium ions are pumped out in exchange for two potassium ions pumped in (2) . If the Na,K pumps are inhibited, the reduced sodium extrusion would increase the internal sodium content of erythrocytes (ENa) (3). Although erythrocyte membrane Na,K-ATPase activity in essential hypertensive patients has been studied extensively, the effects of calcium channel blockers on the activity of this enzyme have not been fully investigated.
Because modification of intracellular concentrations of calcium may play a crucial role in the regulation of Na,K-ATPase activity (4), we undertook the present study to determine Na,K-ATPase activity in hypertensive patients during the therapeutic response to slow-release calcium channel blockers.
Subjects and Methods

Study Populations
The control normotensive subjects were eight men and seven women, ages 40-65 (mean ± SD, 49.7 ± 7.6) years. The mean ± SD (range) values of systolic and diastolic blood pressures of the normal controls were 125.33 ± 11.25 mmHg (110-140) and 76.33 ± 4.42 mniHg (70-80), respectively, as determined by repeated examinations in the supine position. No case of hypertension was known to be the cause of death in the family of this group, and all living relatives were normotensive. The group is representative of the general population.
The hypertensive patients we studied were seven men and eight women, ages 38-64 (48.8 ± 9.5) years. Blood pressure measurements were made between 1000 and 1200, after the patients had rested for 5 miii in a supine position; systolic and diastolic blood pressures were measured three times at 2-mm intervals and the mean of these three determinations was used. Systolic blood pressures were recorded at the first tapping sound (Korotkoff phase I) and diastolic blood pressures were recorded at the point of complete disappearance of the sound (Korotkoff phase V). These patients' systolic and diastolic blood pressure values were 169 ± 13.52 and 108.67 ± 9. 15 
Results
Our results are summarized in Table 1 . ENa was significantly higher (P <0.0001) and Na,K-ATPase activity significantly lower (P <0.0001) in the hypertensive group before treatment than in the controls; after treatment, ENa decreased and Na,K-ATPase activity increased, becoming significantly different (P <0.0001 and P <0.00 1, respectively) from pretreatment values and not different from the control group (Table 1) .
The correlation between ENa and enzyme activity was significant and negative both in the control group and the posttreatment group: r = -0.608 (P <0.05) and r = -0.724 (P <0.01), respectively (Fig. 1) . In our experiment (n = 30), we observed significant negative correlations between Na,K-ATPase activity and systolic, diastolic, and mean blood pressure values: r = -0.598 (P <0.0001), r = -0.628 (P <0.001), and r = -0.635 (P <0.001), respectively. Positive correlations were also found between ENa contents and systolic, diastolic, and mean blood pressure values: r = 0.615 (P <0.001), r = 0.705 (P <0.0001), and r = 0.689 (P <0.001), respectively. Correlation analyses were done with pooled samples from the normal control group and from the hypertensive subjects before treatment. However, we saw no significant correlation between the reduction of systolic and diastolic blood pressures and the increase of the enzyme activity (n = 15): r = -0.048 and r = -0.477, respectively (Table 3) .
Discussion
Whether the defect of Na' metabolism is a cause or a consequence of essential hypertension is controversial.
Kesteboot
and Joossens (9) and Blaustein (3) concluded that, although cations are thought to play an important role in the genesis of hypertension, little attention has been given to the relation between serum, intracellular cations, and blood pressure, partly because the concentrations of these cations remain within such strict limits that they appear unlikely to exert a major influence on blood pressure.
Michel et al. (10) pointed out that one error of Na metabolism can be an abnormal function of Na,KATPase, which may lead to hypertension through cellular retention of Na in vascular smooth muscle. Several studies of the changes in Na,K-ATPase activity in essential hypertensive patients have given conflicting results, reporting both increased (11) (12) (13) and decreased (10, 14-16) activities.
Lechi et al. (16) concluded that these discrepancies could be accounted for partly by the different assay methods used and partly by a hypothetical increased circulatory inhibitor action on sodium pumps in hypertensive patients. Indeed, a circulating ouabain-like natriuretic factor inhibits the Na,K- (18) .
Our results indicate that nitrendipine lowered blood pressure in almost all of the patients (Table 2) . Previously, we found a significant correlation between age and Na,K-ATPase activity (P <0.001, r = -0.519, n = 44) (19), as had others (20-23). Because our observations emphasize an age-related decline in Na,KATPase activity, we wanted to limit our study to the same age group and therefore to nitrendipine responders. Our findings imply that age is a very decisive factor in shaping the Na,K-ATPase response to calcium channel blockers.
In our results, the difference in EK concentrations between control and hypertensive groups was also significant (P <0.0001). with calcium antagonists fails to control blood pressure sufficiently, these drugs can be safely combined with angiotensinconverting enzyme inhibitors, diuretics, and beta blockers. Many patients do not benefit from monotherapy with Ca2 antagonists, but others are highly responsive (25) .
In our experiment, the essential hypertensive patients had significantly higher enzyme activities after treatment with calcium antagonists.
However, relative changes in enzyme activity in relation to the relative reduction in blood pressure response to treatment were not correlated.
In conclusion, therefore, erythrocyte membrane Na,K-ATPase activity is not useful as a marker for screening hypertensive patients to determine who may benefit from treatment with calcium antagonists.
We propose that individual variations in the erythrocyte membrane Na,K-ATPase activity may underlie this divergent responsiveness.
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